PDL1: The Illusion of an Ideal Biomarker

European Urology Focus

Volumn 1, Issue 3, 2016, Pages 269-271

  Apolo, Andrea B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY 5H1; PDL1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MOLECULAR DYNAMICS; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84959180422     PISSN: None     EISSN: 24054569     Source Type: Journal    
DOI: 10.1016/j.euf.2015.04.005     Document Type: Editorial

References (18)

1. Powles T., Eder J.P., Fine G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
2. Plimack E., Gupta S., Bellmunt J., et al. LBA23 - a phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (pts) with advanced urothelial tract cancer. Ann Oncol 2014, 25:1-41.
3. Inman B.A., Sebo T.J., Frigola X., et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007, 109:1499-1505.
4. Boorjian S.A., Sheinin Y., Crispen P.L., et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008, 14:4800-4808.
5. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
6. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
7. Herbst R.S., Soria J.C., Kowanetz M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
8. Dummer R., Daud A., Puzanov I., et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. J Transl Med 2015, 13(Suppl 1):O5.
9. Grosso J., Horak C., Inzunza D., et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract 3016]. J Clin Oncol 2013, 31(Suppl).
10. Hamid O., Sosman J., Lawrence D., et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM) [abstract 9010]. J Clin Oncol 2013, 31(Suppl).
11. Motzer R., Rini B., McDermott D., et al. Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial [abstract 5009]. J Clin Oncol 2014, 32.
12. McDaniel AS, Alva A, Zhan T, et al. Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma. Eur Urol Focus. In press.
13. Bracci L., Schiavoni G., Sistigu A., Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014, 21:15-25.
14. Gulley J.L., Arlen P.M., Bastian A., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005, 11:3353-3362.
15. Apolo A., Tomita Y., Lee M., et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma [abstract 4501]. J Clin Oncol 2014, 32.
16. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
17. Taube J.M., Klein A., Brahmer J.R., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014, 20:5064-5074.
18. Taube J.M., Anders R.A., Young G.D., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4:127ra37.